Coave Therapeutics
Rodolphe Clerval has extensive experience in the biotechnology industry. Rodolphe is currently the Chief Executive Officer of Coave Therapeutics, a clinical stage genetic medicine company. Rodolphe joined the company in 2020 as the Chief Business Officer before assuming their current role. Prior to Coave Therapeutics, Clerval was the Co-founder and Chief Business Officer - VP US Operations at Enterome Bioscience from 2011 to 2020. Rodolphe also served as the President of MedValue SAS from 2011 to 2013. Before that, Clerval worked as the Vice President of Corporate and Business Development at TcLand Expression from 2008 to 2010. Rodolphe started their career as a Business Development Manager at Genzyme Europe B.V. from 2004 to 2008. Clerval worked as an Equity Analyst Pharmaceuticals at Natixis from 2001 to 2004, where they conducted strategic and financial analysis of public Pharma/Biotech companies. Rodolphe began their professional journey as a Scientist at AVENTIS from 1998 to 2000.
Rodolphe Clerval completed their MSc in Biochemical Engineering from Polytech Marseille between 1995 and 1998. From 2001 to 2003, they pursued a degree in Corporate Finance from CIIA/SFAF. Additionally, between 1998 and 2000, they were a Visiting Scientist at ETH Zurich, specializing in an unspecified field of study.
Coave Therapeutics
Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases. Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.